Machine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimer’s Disease

Manuscript Number: 

19-0822R2

Author(s): 
Ali Ezzati, Richard B. Lipton

Disclosures

Ali Ezzati

  • Consulting Fees:
    Eisai

Richard B. Lipton

  • Consulting Fees:
    Dr. lipton serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff’s Headache 7th and 8th Edition, Oxford Press University, 2009, Wiley and Informa.
    Equity:
    Dr. Lipton holds stock options in eNeura Therapeutics and Biohaven Holdings;